CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
3'-deoxy-3'-(18) F-fluorothymidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01243619
NCT01243619N/ACompleted
CompareCT.gov

3'-Deoxy-3'(18) F-Fluorothymidine Positron Emission Tomography/Computed Tomography (PET/CT) for Initial Staging, Radiotherapy Target Definition, and Assessment of Response to Therapy in Patients With Esophageal Cancer: A Pilot Study

Dana-Farber Cancer Institute·interventional·Posted Nov 18, 2010·Updated May 17, 2017

In Brief

A clinical study evaluating 3'-deoxy-3'-(18) F-fluorothymidine for Esophageal Cancer. Completed, enrolled 5 participants across 3 sites.

Detailed Summary

The purpose of this pilot study is to develop a more advanced software program that will collect, compare and analyze tumor images for evaluation. Another purpose of this study is to learn if a new radio-tracer for tumor imaging called 3'-deoxy-3'(18) F-fluorothymidine (FLT) can improve the evaluation of tumors during a PET/CT scan. This new type of image tracking is meant to improve the visualization of tumor active and size.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
CollaboratorsBrigham and Women's Hospital

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2010
Enrollment StartAug 1, 2010
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.6 years ago

Interventions

3'-deoxy-3'-(18) F-fluorothymidinedrug

Radio-tracer for tumor imaging